Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

NSF International Aquires Majority Interest in Amarex CRO

Amarex founder Dr. Kazem Kazempour will continue as president and CEO of Amarex, an NSF International company.

The transaction generates a single access point for medical device and pharma / biotech product creators seeking integrated, expert services throughout the whole product lifecycle.

Global public health organization NSF International has acquired a majority interest in Amarex Clinical Research, LLC, a clinical-stage contract research organization (CRO) headquartered in Germantown, Maryland. The transaction supports NSF International’s mission of protecting and improving human health through expanded consulting services to the medical device and pharma / biotech industries. As part of NSF International’s global health science consulting business, the highly-respected CRO will be known as Amarex Clinical Research, LLC, an NSF International company.

Amarex Clinical Research, LLC will gain access to NSF International’s expert network and international scope. As part of NSF’s global network of locations, Amarex will continue to operate from its US office near Washington, DC. The company also operates an office in Taiwan and has a developing presence in Europe.

“NSF International plays an important role in the pharmaceutical and biotech industry as a champion of quality, scientific rigor and best practices aimed at protecting and improving human health. Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International President and CEO Kevan Lawlor. “Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”

“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and CEO of Amarex, an NSF International company. “NSF International’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device / diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”

Since 1998, Amarex Clinical Research has been helping biotech, medical device and pharmaceutical companies conduct scientifically sound clinical trials and navigate complex regulatory environments in a wide range of therapeutic indications, including oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.

As part of NSF International, Amarex will support companies with regulatory affairs, project / trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.

Find out more about NSF health sciences’ services by filling out the enquiry form attached to this page.

More About This Company